LISA BUCHANON: Open Payments
NPI 1710586623 · ONEONTA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 42 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $298 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $181 |
| ABBVIE INC. | 6 | $146 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $85 |
| Novo Nordisk Inc | 4 | $72 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Amgen Inc. | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $36 |
| Exact Sciences Corporation | 2 | $32 |
Products named: VRAYLAR, CAPLYTA, AIRSUPRA, Ozempic, XIFAXAN, FANAPT, FARXIGA, GEMTESA.
Industry payments across AL — which companies pay providers there.
